Back to search results

Endovascular Rescue Therapy for Brain Stroke with Underlying Intracranial Stenosis

This study is looking at how safe and effective two different treatments are for people who have had a brain stroke (acute ischemic stroke). Both treatments involve mechanical thrombectomy, which is a procedure to remove a blood clot. One group will receive mechanical thrombectomy only. The other group will receive mechanical thrombectomy plus adjunct stenting, where a small tube (stent) is placed to keep the artery open. You might be able to join if you are between 18 and 80 years old, have symptoms of an acute ischemic stroke, and imaging shows a blockage in a main brain artery with significant narrowing (70-99% stenosis) remaining after an attempt to remove the clot. The study aims to see how well these treatments work and if they are safe, with results measured about 90 days after treatment. The current recruitment status is unclear.

Study design
This is an interventional study planning to enroll 342 participants. It compares two different procedures for treating stroke.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
Participants will be followed for safety and effectiveness for about 90 days after treatment.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07356284

Emergent Large Vessel Occlusion Endovascular Rescue Therapy With Underlying Intracranial Stenosis

Recruiting
PHASE3Ages 18–80InterventionalTreatment
ProMedica Health System
~342 participants
Updated 2026-05-22 on ClinicalTrials.gov
What's tested:Mechanical Thrombectomy plus adjunct stentingMechanical Thrombectomy

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Primary Efficacy Endpoint
Measured over 90 (+/- 30) days post treatment
+1 more outcome measured

Conditions

Brain Stroke
Stenting Treatment
Acute Ischemic Stroke

Explore related trials

Acute Ischemic Stroke

NCT07356284

Where you'd take part

This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • ProMedica Toledo Hospital

    Toledo, Ohiostudy coordinator listed

    Recruiting

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

  • Sami Al Kasab, MD · PRINCIPAL_INVESTIGATOR · Medical University of South Carolina
  • Mouhammad Jumaa, MD · PRINCIPAL_INVESTIGATOR · ProMedica Toledo Hospital
  • Tanya Siddiqui · STUDY_DIRECTOR · ProMedica Health System

Who to contact

Sami Al Kasab, MD
[email protected]
4192913498
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Exclusion

Midline shift or herniation
Evidence of intracranial hemorrhage
Mass effect with effacement of the ventricles 4. Acute bilateral strokes 5. Contraindication to antiplatelet (aspirin, clopidogrel, ticagrelor, cangrelor) or contrast agents 6. Intracranial tumors other than small meningioma, that do not require surgery for at least one year post randomization. Small meningioma is defined as a lesion measuring ≤20mm in maximum diameter or ≤4cm3 in volume, with no associated mass effect, peritumoral edema, or progressive neurological symptoms 7. Known hemorrhagic diathesis, coagulation factor deficiency, or on anticoagulant therapy with an International Normalized Ratio (INR) of \>3.0 or Partial Thromboplastin Time (PTT) \>3 times of normal 8. Baseline platelet count \<80,000 per microliter (µl) 9. Life expectancy less than one year prior to stroke onset 10. Participation in another randomized clinical trial that could confound the evaluation of the study outcomes. 11. Any other condition (in the opinion of the site investigator) that precludes an endovascular procedure or poses a significant hazard to the patient if an endovascular procedure was performed 12. New diagnosis of atrial fibrillation or a history of atrial fibrillation 13. Suspected device-induced vasospasm defined as smooth transient narrowing of the target vessel 14. Vessel dissection including any of the following: presence of dissection flap, false lumen, contrast stagnation in the vessel wall, and/or improving stenosis

What this trial measures

  • Primary Efficacy Endpoint90 (+/- 30) days post treatment

    • Utility weighted 90-day Modified Rankin Score (mRS)

  • Primary Safety Endpoint90 (+/- 30 ) days post treatment

    Rate of symptomatic intracranial hemorrhage (sICH: Parenchymal hematoma Type 2 (PH2) with ≥4 points NIHSS worsening) at 24 hours (-12/+16 hours) from randomization)